ProCE Banner Activity

STIMULUS-MDS1: Randomized, Placebo-Controlled Phase II Trial of Sabatolimab, a TIM-3 Inhibitor, Plus HMA in Higher-Risk MDS

Slideset Download
Conference Coverage

Sabatolimab plus a hypomethylating agent (azacitidine or decitabine) did not yield statistically significant improvement in CR and PFS in patients with higher-risk MDS.

Released: December 13, 2022

Expiration: December 12, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen